Overall survival in patients with advanced melanoma who received Nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial - Larkin, James; Hassel, Jessica C. (Journal of clinical oncology, 2018)
Published online July 03, 2017